Announcements Trials

Browse Landscape

Phase

Status

Completed 46 Unknown 8 Terminated 4 Recruiting 3 Approved for marketing 3 Withdrawn 1 Suspended 1 Enrolling by invitation 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 2 pembrolizumab 1 osimertinib 1 icotinib 1 famitinib 1 dabrafenib 1 cemiplimab 1 alirocumab 1 aldesleukin 1 Surgical Procedures, Operative 1 Specimen Handling 1 Radiotherapy 1 Radiation 1 Pemetrexed 1 Panitumumab 1 Monatide (IMS 3015) 1 Magnetic Resonance Spectroscopy 1 Ipilimumab 1 Interleukin-2 1 Injections 1 Immune Checkpoint Inhibitors 1 Gefitinib 1 Eflornithine 1 Drug Therapy 1 Cisplatin 1 Celecoxib 1 CTLA-4 Antigen 1 Blood Specimen Collection 1 Biopsy 1 Biological Products 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Carcinoma, Non-Small-Cell Lung × Afatinib × Clear all

NCT02470065 2016-01-22

REMNANT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Suspended

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡